Get the app
NSEHealthcare

Bal Pharma Limited (BALPHARMA)

NSE · Healthcare · Drug Manufacturers - Specialty & Generic

₹102.46+1.12%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
₹89 cr
Revenue YoY
+34.5%
Net profit
₹1 cr
Profit YoY
+460.1%
Net margin
1.3%

Key statistics

Market cap
₹171 cr
P/E
23.7
Forward P/E
0.0
P/B
2.08
Book value
₹51.71
EPS (TTM)
₹4.53
52-week high
₹124.60
52-week low
₹60.00
50-day MA
₹87.82
200-day MA
₹78.73
Beta
0.45

Shareholding

Promoters
65.28%

Recent filings & reports

DocumentDate
Annual report FY2026
SUMMARY: BAL PHARMA LIMITED - FY 2025-26 ANNUAL REPORT HEADLINE NUMBERS • Total Income (Standalone): Rs. 31,279.99 lakhs (FY 2025-26) vs Rs. 30,464.
2026-08-26
Quarterly results · Q1 FY27
BAL PHARMA LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Q1 FY2026-27 (Quarter ended 30 June 2026) Standalone Revenue from Operations: ₹8,842.73 Lak
2026-08-12
Quarterly results2026-07-27
Quarterly results · Q4 FY26
BAL PHARMA LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • FY 2025-26 Revenue from Operations: Rs. 31,079.70 lakhs (vs Rs. 30,249.64 lakhs in FY 2024
2026-05-27
Quarterly results · Q3 FY26
BAL PHARMA LIMITED – Q3 FY2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q3 FY2026 (Quarter ended 31-Dec-2025) Standalone Results: - Revenue from opera
2026-02-11
Quarterly results · Q2 FY26
BAL PHARMA LIMITED – DOCUMENT SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Q2 FY2026 (Quarter ended 30 Sep 2025) – Standalone: - Revenue from o
2025-11-12
Annual report FY2025
BAL PHARMA LIMITED – ANNUAL REPORT FY 2024-25 SUMMARY HEADLINE NUMBERS • Dividend declared: Re.1.20 per Equity Share of Rs 10/- each • Financial yea
2025-09-02
Quarterly results · Q1 FY26
BAL PHARMA LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Q1 FY2026 Standalone Revenue: ₹6,563.51 lakhs (quarterly unaudited) • Q1 FY2026 Standalone
2025-08-11

Readable in the app.

Corporate actions

ActionDetailDate
Dividend₹1.20 / share
ex-date Sep 17, 2026
2026-09-17
Dividend₹1.20 / share
ex-date Sep 18, 2025
2025-09-18

Deals & corporate news

AnnouncementDate
Approved investment in proposed joint venture entity in Philippines
Bal Pharma Limited's board approved five key decisions on August 12, 2026: 1. **Q1 FY2027 Results**: Approved unaudited financial results for the quarter ended June 30, 2026, with auditor's
2026-08-12

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bal Pharma Limited — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.